Innovative antibody shows promise for personalised cancer treatment

Scientists from Uppsala University and KTH Royal Institute of Technology have developed a new type of antibody that could lead to safer and more effective cancer treatments.
This ‘3-in-1’ antibody works by combining three important functions: targeting cancer cells, delivering a drug directly to these cells, and activating the immune system to attack the cancer cells more strongly.
This research, published in Nature Communications, describes how the antibody boosts the effect of T cells – the body’s natural cancer-fighting cells – on tumours. The antibody both targets specific mutations found only in cancer cells (called neoantigens) and stimulates immune cells, which increases their response against the tumour.
Lead authors Sara Mangsbo, Professor at the Department of Pharmacy at Uppsala University, and Johan Rockberg, Professor at KTH, explain that this approach is designed for precision medicine, where treatments are tailored to each patient’s cancer. The new antibody has shown promising results in early tests; in blood samples, it activated the right immune cells and in animal tests it extended survival in mice and, at higher doses, even helped prevent some from developing cancer. Importantly, this approach also appears safer than many current treatments.
Additionally, the drug is designed to be easier and faster to produce. It consists of two parts: a bispecific antibody that can be mass-produced, and a custom-made peptide that can be quickly prepared for each patient’s specific cancer. According to Rockberg, “This setup reduces production costs and shortens the time needed to tailor the drug for individual patients, allowing them to start treatment sooner.”
The team’s goal is to create a cancer treatment that is more flexible, faster acting, and safer than existing options. Next, they plan to prepare the drug for human safety studies, with the aim of beginning clinical trials soon.
“We have been researching precision medicine for close to 15 years now, as well as how we can use antibodies to influence an important key protein (CD40) in the immune system,” commented Mangsbo. “We can now show that our new antibody method works as precision medicine for cancer.”
Source:
New antibody could be promising cancer treatment [Accessed November 12, 2024] https://www.eurekalert.org/news-releases/1064404
Related News
-
News CPHI Podcast Series: What does an evolving pharmaceutical industry mean for excipients?
In the first episode of the CPHI Podcast Series for 2025, Evonne Brennan speaks about the future of the excipient field in pharma, and what challenges and changes could be on the horizon. -
News Orbis Medicines receives funding for the development of oral biologics
Orbis Medicines, a biotechnology company based in Denmark, has recently achieved a significant milestone in its funding journey. The company has successfully secured €90 million ($94 million) in a Series A funding round, marking a substantial boos... -
News SCHOTT Pharma’s sustainable journey with CPHI
Sustainability is of paramount importance in the pharmaceutical industry. See how a recent partnership between CPHI and SCHOTT Pharma has helped to highlight and accelerate their sustainability journey to reach global goals. -
News Novavax sells Czech production plant to Novo Nordisk for $200M
Novavax has sold its Czech manufacturing facility to Novo Nordisk for $200 million, including the site’s 300 employees, in a move to cut costs and focus on vaccine development. -
News Pharmapack 2025 Track Sponsor Interview: Terumo on the importance of packaging innovation
At Pharmapack 2025 in Paris in January, the conference theatre will once again be hosting insightful discussions across several key topics in the pharmaceutical packaging field. One track, Device and Packaging Innovation will be sponsored by Terumo. ... -
News Inspiration, Innovation, Impact – Get Ready for Pharmapack 2025
This article goes into depth about waht you can expect to find on site at Pharmapack 2025, taking place in Hall 7.2 of the Porte de Versaille in Paris, France on the 22nd and 23rd January. -
News AI-driven drug discovery model sets new accuracy prediction benchmark
Iambic Therapeutics, an Nvidia-backed biotech based in London, have stated that their AI drug discovery model named ‘Enchant’ demonstrates the potential to reduce the time and cost associated with new drug development. -
News Biopharmaceutical manufacturing boost part of new UK government budget
In their national budget announced by the UK Labour Party, biopharmaceutical production and manufacturing are set to receive a significant boost in capital grants through the Life Sciences Innovative Manufacturing Fund (LSIMF).
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance